Imiquimod
- 1 October 2003
- journal article
- editorial
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 139 (10) , 1347-1350
- https://doi.org/10.1001/archderm.139.10.1347
Abstract
Opinion from JAMA Dermatology — Imiquimod — A Topically Applied Link Between Innate and Acquired ImmunityKeywords
This publication has 32 references indexed in Scilit:
- Mechanisms Underlying Imiquimod-Induced Regression of Basal Cell Carcinoma In VivoArchives of Dermatology, 2003
- A Randomized, Double-blind, Vehicle-Controlled Study to Assess 5% Imiquimod Cream for the Treatment of Multiple Actinic KeratosesArchives of Dermatology, 2002
- Treatment of Stage IA Cutaneous T-Cell Lymphoma With Topical Application of the Immune Response Modifier ImiquimodArchives of Dermatology, 2002
- Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicenter 6-week dose-response trialJournal of the American Academy of Dermatology, 2001
- Self‐administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosumBritish Journal of Dermatology, 2000
- Imiquimod: a novel treatment for lentigo malignaBritish Journal of Dermatology, 2000
- Self-administered Topical 5% Imiquimod Cream for External Anogenital WartsArchives of Dermatology, 1998
- Cytokine induction by the immunomodulators imiquimod and S-27609Journal of Leukocyte Biology, 1995
- Induction of Interferon and Other Cytokines by Imiquimod and Its Hydroxylated Metabolite R-842 in Human Blood Cells In VitroJournal of Interferon Research, 1994
- Cytokine induction in mice by the immunomodulator imiquimodJournal of Leukocyte Biology, 1994